Xeris Biopharma Holdings, Inc. (XERS) Stock

Xeris Biopharma Holdings, Inc. (XERS) is a Healthcare stock trading at $8.69 (as of 2026-08-21), with a market capitalization of $1.50B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company that develops and commercializes therapies for patient populations in endocrinology, neurology, and gastroenterology. Its marketed products include Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis variants, and Recorlev for endogenous hypercortisolemia in adults with Cushing’s syndrome, with additional development programs and formulation platforms XeriSol and XeriJect.

Understand Xeris Biopharma Holdings, Inc.: how it makes money

Xeris Biopharma develops and commercializes biopharmaceutical therapies, including Gvoke (ready-to-use liquid glucagon for severe hypoglycemia), Keveyis (for primary periodic paralysis variants), and Recorlev (for endogenous hypercortisolemia in adult Cushing's syndrome), and it makes money mainly from product sales of these therapies.

Xeris' profit engine is the repeatable commercialization of its marketed therapies (especially Recorlev and Gvoke), where product revenue is the dominant source of revenue versus collaborations and other non-product items.

Revenue by segment (latest quarter)
Recorlev	$0.1B
Gvoke	$0.0B
Keveyis	$0.0B
Caveas	$0.0B
Other	$0.0B

Business quality (Strong): Clear commercial product focus across endocrinology, neurology, and gastroenterology (Gvoke, Keveyis, Recorlev), but the model appears heavily driven by product sales, which increases sensitivity to product performance and market dynamics, while pipeline progress adds execution risk.

Valuation: At 86× earnings, XERS trades 409% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

Multiple marketed therapies across distinct patient needs: The company markets Gvoke for severe hypoglycemia, Keveyis for variants of primary periodic paralysis, and Recorlev for endogenous hypercortisolemia in adult Cushing's syndrome, which supports a diversified commercial offering within biopharmaceutical products.
Product revenue is the core driver: For the latest period, Product Revenue, Net is 0.08B, and major components include Recorlev Revenue at 0.05B and Gvoke Revenue at 0.02B, indicating profitability is anchored in marketed product sales.

Bear case

Dependence on a limited set of commercial products: With revenue largely tied to marketed therapies (and non-product categories shown as 0.0 in the provided data), outcomes for Gvoke, Keveyis, and Recorlev can materially influence results.
Pipeline execution risk: The company has development programs in addition to its marketed products, which introduces uncertainty around clinical, regulatory, and commercial execution before additional revenue sources can be realized.

Valuation — source: SEC EDGAR (first-party)
Price	$8.69
Market Cap	$1.50B
EV / EBITDA	87.7
Price / Book	115.31
Price / Sales	5.19
DCF Value (model)	$1.52
DCF Upside vs Price	-82.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$291.85M
Net Margin	0.2%
Revenue Growth (YoY)	43.7%
EPS Growth (YoY)	-100.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.36 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($87.82M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	John Shannon
Employees	394
Country	US
IPO Date	2018-06-21

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.